Pfizer Inc. (PFE) on Wednesday reported positive topline results from the Phase 3 MagnetisMM-5 study evaluating ELREXFIO in adults with relapsed or refractory multiple myeloma who had received at least one prior line of treatment.
The study met its primary endpoint, showing a statistically significant improvement in progression-free survival compared with standard-of-care daratumumab plus pomalidomide and dexamethasone.
The safety and tolerability profile of ELREXFIO was consistent with prior studies, with most treated patients remaining progression-free at the interim analysis. The trial is ongoing to assess overall survival, which was not yet mature at the time of analysis.
ELREXFIO is already approved in more than 35 countries, including the United States and the European Union for certain patients with relapsed or refractory multiple myeloma.
On Tuesday, Pfizer shares closed at $26.48, down 1.16%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.